Biotech Strategy Blog

Commentary on Science, Innovation & New Products with a focus on Oncology & Hematology

Will Bluebird Bio transform beta Thalassemia and Sickle Cell Anemia?

Beta thalassemia isn’t something you read much about in the medical lay press, at least until recently.  Part of the problem is the lack of approved therapies, as well as the dearth of new products being evaluated in this condition.  It’s also more common in the Mediterranean, Middle East and Asia compared to the US, where it’s medical cousin, sickle cell anemia, dominates.

Leave a comment

Biomarin PARP inhibitor talazoparib shows promise in gBRCA Breast Cancer

The DNA in a human cell undergoes thousands damaging events per day, generated by both external (exogenous) and internal metabolic (endogenous) processes. Unfortunately, some of these changes can generate errors in the transcription of DNA and subsequent translation into proteins necessary for signaling and cellular function. Genomic mutations can also be carried over into future generations of cells, if the mutation is not repaired prior to mitosis.

Leave a comment

ASH 2014 Day 3 Live blog #ASH14

San Francisco – “Manic Monday” is what I call Monday at the annual meeting of the American Society of Hematology. It’s when the majority of oral presentations take place in multiple parallel sessions that require you to run between meeting rooms if you want to follow a particular drug across different blood cancers.

Leave a comment
error: Content is protected !!